BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: Dec 3, 2025 · CIK: 882796
Sentiment: neutral
Topics: reporting, financials
Related Tickers: BCRX
TL;DR
BioCryst filed a routine 8-K, no major news.
AI Summary
On December 3, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other events detailed beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates standard corporate reporting and does not disclose any new material events that would immediately impact BioCryst Pharmaceuticals' stock.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, indicating no new material events or significant changes.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- December 3, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for BioCryst Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is December 3, 2025.
Under which section of the Securities Exchange Act of 1934 is BioCryst Pharmaceuticals, Inc. filing this report?
BioCryst Pharmaceuticals, Inc. is filing this report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is BioCryst Pharmaceuticals, Inc.'s principal executive office address?
BioCryst Pharmaceuticals, Inc.'s principal executive office is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
Does this 8-K filing indicate any specific 'Other Events' beyond standard reporting?
The filing lists 'Other Events' as an item information category, but the content provided does not detail any specific material events beyond the standard reporting of financial statements and exhibits.
Filing Stats: 1,570 words · 6 min read · ~5 pages · Grade level 14.6 · Accepted 2025-12-03 08:00:56
Filing Documents
- ef20060538_8k.htm (8-K) — 38KB
- ef20060538_ex99-1.htm (EX-99.1) — 14KB
- image0.jpg (GRAPHIC) — 339KB
- 0001140361-25-044110.txt ( ) — 653KB
- bcrx-20251203.xsd (EX-101.SCH) — 4KB
- bcrx-20251203_lab.xml (EX-101.LAB) — 21KB
- bcrx-20251203_pre.xml (EX-101.PRE) — 16KB
- ef20060538_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On December 3, 2025, BioCryst Pharmaceuticals, Inc. ("BioCryst") issued a press release announcing early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to its previously announced proposed acquisition (the "Merger") of Astria Therapeutics, Inc. ("Astria"). A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions. Cautionary Statement Regarding Forward-Looking Statements identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking "may," "approximately," "continue," "should," "expects," "projects," "anticipates," "is likely," "look ahead," "look forward," "believes," "will," "intends," "estimates," "strategy," "plan," "could," "potential," "possible" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include statements regarding, among other things, the anticipated timing of the closing of the Merger and BioCryst's and Astria's plans, objectives, expectations, intentions, growth strategies and other statements that are not histo
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release dated December 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCRYST PHARMACEUTICALS, INC. Date: December 3, 2025 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer